Retatrutide is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors.

Triple Mechanism

Retatrutide adds glucagon activation to increase energy expenditure beyond dual agonists.

Research Results

• Up to 24% body weight loss in trials
• Superior to tirzepatide
• Liver fat reduction benefits

Current Status

Retatrutide is in Phase 3 trials. Research-grade available from peptide suppliers.

Dosing

Titration starts at 0.5mg weekly, increasing to 12mg.

Research peptides are NOT equivalent to approved pharmaceuticals.